First human test for new COVID-19 antibody treatment begins
NCT ID NCT07156864
Summary
This is an early safety study for a new lab-made antibody drug called B10-FC, designed to treat COVID-19 early in the illness. It will first test single doses in a small group of healthy adults, then in adults who have recently tested positive for COVID-19 and have mild to moderate symptoms. The main goal is to see if the drug is safe and how the body handles it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.